Effect of Interstitial Lung Disease Subtypes on COVID-19 Mortality
How does the COVID-19 mortality rate vary among patients with different subtypes of interstitial lung disease?
How does the COVID-19 mortality rate vary among patients with different subtypes of interstitial lung disease?
How does IPF increase risk for lung cancer morbidity/mortality? Researchers analyzed the potential mechanisms for this, which may represent new therapeutic targets.
A recent update of IPF clinical practice guideline addresses the progression of pulmonary fibrosis in patients with interstitial lung diseases other than IPF.
In patients with idiopathic pulmonary fibrosis, can supplementation with vitamins C, D, and E affect respiration, inflammation, and oxidative stress?
What characterizes the progressive fibrosing ILD phenotype, and what baseline factors associated with this phenotype may help guide clinical decision making?
What is the real-world effectiveness and safety of nintedanib in patients with idiopathic pulmonary fibrosis?
BI 1015550 is an investigational oral phosphodiesterase 4B inhibitor with combined antifibrotic and anti-inflammatory effects.
What is the diagnostic value of Krebs von den Lungen-6 (KL-6) in diagnosing and determining the severity of idiopathic pulmonary fibrosis?
How effective are the antifibrotic agents nintedanib and pirfenidone for patients with idiopathic pulmonary fibrosis and non-IPF?
Can a certain level of daily physical activity improve the prognosis for patients with idiopathic pulmonary fibrosis?